Synthesis and evaluation of a bromine-76-labeled PPARγ antagonist 2-bromo-5-nitro-N-phenylbenzamide

Nuclear Medicine and Biology

Volumn 33, Issue 7, 2006, Pages 847-854

  Lee, Hsiaoju ^a   Finck, Brian N ^b   Jones, Lynne A ^a   Welch, Michael J ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antagonist; Breast tumor imaging agent; PPAR

Indexed keywords

2 BROMO 5 NITRO N PHENYLBENZAMIDE; 2 BROMO 5 NITRO N PHENYLBENZAMIDE BR 76; 2 BROMO 5 NITRO N PYRIDIN 4 YLBENZAMIDE; 2 BROMO 5 NITRO N PYRIDIN 4 YLBENZAMIDE BR 76; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITRO N PYRIDIN 4 YLBENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 2 FLUORO 5 NITRO N PHENYLBENZAMIDE; 2 FLUORO 5 NITRO N PYRIDIN 4 YLBENZAMIDE; BROMINE DERIVATIVE; HALOGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BREAST TUMOR; CANCER MODEL; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DEGRADATION KINETICS; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; METABOLIC REGULATION; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA; RECEPTOR BINDING; SUBSTITUTION REACTION; WHOLE CELL;

ANILIDES; ANIMALS; BENZAMIDES; BREAST NEOPLASMS; BROMINE RADIOISOTOPES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; PPAR GAMMA; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33749453406     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.08.003     Document Type: Article

References (26)

1. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
2. Kota B., Huang T.H., and Roufogalis B. An overview on biological mechanisms of PPARs. Pharmacol Res 51 (2005) 85-94
3. Mueller E., Sarraf P., Tontonoz P., Evans R.M., Martin K.J., Zhang M., et al. Terminal differentiation of human breast cancer through PPARg. Mol Cell 1 (1998) 465-470
4. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S., et al. Effects of ligand activation of peroxisome proliferator-activated receptor g in human prostate cancer. Proc Natl Acad Sci U S A 97 20 (2000) 10990-10995
5. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., et al. Differentiation and reversal of malignant changes in colon cancer through PPARg. Nat Med 4 9 (1998) 1046-1052
6. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., et al. PAX8-PPARg1 fusion oncogene in human thyroid carcinoma. Science 289 (2000) 1357-1360
7. Heaney A.P., Fernando M., Yong W.H., and Melmed S. Functional PPAR-g receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8 11 (2002) 1281-1287
8. Harris S.G., and Phipps R.P. Prostaglandin D2, its metabolite 15-d-PGJ2, and peroxisome proliferator activated receptor-g agonists induce apoptosis in transformed, but no normal, human T lineage cells. Immunology 105 (2002) 23-34
9. Bildirici I., Roh C.R., Schaiff W.T., Lewkowski B.M., Nelson D.M., and Sadovsky Y. The lipid droplet-associated protein adipophilin is expressed in human trophoblasts and is regulated by peroxisomal proliferator-activated receptor-r/retinoid X receptor. J Clin Endocrinol Metab 88 12 (2003) 6056-6062
10. Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., et al. PPARg ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110 (2002) 923-932
11. Burstein H.J., Demetri G.D., Mueller E., Sarraf P., Spiegelman B.M., and Winer E.P. Use of the peroxisome proliferator-activated receptor (PPAR) ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79 3 (2003) 391-397
12. Subbarayan V., Xu X.C., Kim J., Yang P., Hoque A., Sabichi A.L., et al. Inverse relationship between 15-lipoxygenase-2 and PPARg gene expression in normal epithelialcompared with tumor epithelia. Neoplasia 7 3 (2005) 280-293
13. Nwankwo J.O., and Robbins M.E. Peroxisome proliferator-activated receptor-g expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 64 4&5 (2001) 241-245
14. Clay C.E., Namen A.M., and Atsumi G. Influence of J-series prostaglandins on apoptosis and tumorigenesis of breast-cancer cells. Carcinogenesis 20 (1999) 1905-1911
15. Mehta R.G., Williamson E., Patel M.K., and Koeffler H.P. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92 (2000) 418-423
16. Elstner E., Muller C., and Koshizuka K. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast-cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 95 (1998) 8806-8811
17. Burstein H.J., Demetri G.D., Mueller E., Sarraf P., Spiegelman B.M., and Winer E.P. Use of the perosisome proliferator-activated receptor (PPAR) g ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Research and Treatment 79 (2003) 391-397
18. Sabichi A.L., Kim J., Llansa N., Logothetis C.J., Lippman S.M., et al. Differential peroxisome proliferator-activated receptor-g isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13 11 (2004) 1710-1716
19. Jiang W.G., Douglas-Jones A., and Mansel R.E. Expression of peroxisome-proliferator activated receptor-gamma (PPARg) and the PPARg co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 106 (2003) 752-757
20. Allred C.D., and Kilgore M.W. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235 1-2 (2005) 21-29
21. Hu E.D., Kim J.B., Sarraf P., and Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARg. Science 274 (1996) 2100-2103
22. Kim S., Johnson S.D., Welch M.J., and Katzenellenbogen J.A. Fluorine-substituted ligands for the peroxisome proliferator-activated receptor gamma (PPARg): potential imaging agents for metastatic tumors. Bioconjugate Chem 12 (2001) 439-450
23. Mathews W.B., Foss C.A., Stoermer D., Ravert H.T., Dannals R.F., Henke B.R., et al. Synthesis and biodistribution of (11)C-GW7845, a positron-emitting agonist for peroxisome proliferator-activated receptor-{gamma}. J Nucl Med 46 10 (2005) 1719-1726
24. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K., et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor g, functions as an antagonists of biochemical and cellular activities. J Biol Chem 277 22 (2002) 19649-19657
25. Blessing G., Weinreich R., Qaim S., and Stocklin G. Production of 75Br and 77Br via the 75As(3He,3n)75Br and 75As(a,2n)77Br reactions using Cu3As-alloy as a high-current target material. Int J Appl Radiat Isot 33 (1982) 333-339
26. Consoli A., and Devangelio E. Thiazolidinediones and inflammation. Lupus 14 9 (2005) 794-797